Intrathecal Fentanyl
PreclinicalSmall molecule
Intrathecal Fentanyl is one of 140 small molecule programs targeting Cesarean Section. It is currently in Preclinical.
8
Indications
12
Total Trials
0
Active Trials
139
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
83 competitors in Cesarean Section
#DrugCompanyPhaseTrials
1Fentanyl-Morphine
SSeoul National University Hospital
Phase 3
Ondansetron, Dexamethasone
KKing Khaled Eye Specialist Hospital
Phase 3
Acetaminophen/ibuprofen
SSeoul National University Hospital
Phase 3
Sebacoyl Dinalbuphine Ester
LLumosa Therapeutics Co., Ltd.
Phase 3
Morphine - .
RRambam Health Care Campus
Phase 3
Proamatine
TakedaPreclinical
Dynastat
PfizerPreclinical
Duragesic
CCephalon
Preclinical
Versed
CConrado Roberto Hoffmann Filho
Preclinical
Catapres
Boehringer IngelheimPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Cesarean Delivery3 trials
Infiltration1 trial
5 more indications
Caesarean Section1 trial
Large Volume Bupivacaine 0.5% Versus Small Volume in Elective Caesarean Section
Unknown status·—·N/A·NCT02937792·30 enrolled
Cesarean Section1 trial
Preeclampsia1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Intrathecal Fentanyl. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- MMansoura University